Re: Wave LifeSciences exon 51 trial with previously dosed eteplirsen boys
A regular ID who posts on twitter, "ja Hish" just posted a question about Wave's exon 51 program. My response is one of curiosity of how much Sarepta is following that company's progress and perhaps why Sarepta appears to have slowed forward movement on their exon skipping programs.
Just a side reminder that it is coming up on a year of when the company said they would hurry up and meet with EMA to discuss a path forward in getting approval for eteplirsen there and here we are getting close to closing out the third quarter and nary a word about that.
Ahhh, but back to Wave's results --- it will be very enlightening to see the boys who were in Eteplirsen's trial with their baseline and follow up biopsies compared to Wave's baseline and follow up biopsies from any of the boys who managed to do both trials. What do you think?